On May 4, 2020 Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, reported that the Company will host a conference call and live audio webcast on Monday, May 11, 2020 at 5:00 p.m. ET to report its first quarter 2020 financial results and provide a corporate update (Press release, Fate Therapeutics, MAY 4, 2020, https://ir.fatetherapeutics.com/news-releases/news-release-details/fate-therapeutics-webcast-conference-call-reporting-first-5 [SID1234556955]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In order to participate in the conference call, please dial 877-303-6235 (domestic) or 631-291-4837 (international) and refer to conference ID 8623509. The live webcast can be accessed under "Events & Presentations" in the Investors and Media section of the Company’s website at www.fatetherapeutics.com. The archived webcast will be available on the Company’s website beginning approximately two hours after the event.

On May 4, 2020 The board of directors of Eli Lilly and Company (NYSE: LLY) reported that it has declared a dividend for the second quarter of 2020 of $0.74 per share on outstanding common stock (Press release, Eli Lilly, MAY 4, 2020, View Source [SID1234556954]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The dividend is payable June 10, 2020, to shareholders of record at the close of business on May 15, 2020.

On May 4, 2020 IMV Inc. ("IMV" or the "Corporation") (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines to fight against infectious diseases including COVID-19, announced today that it will hold a conference call and webcast on Friday, May 15, 2020 at 8:00 a.m. ET to discuss the company’s first quarter 2020 financial and operational results.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Financial analysts are invited to join the conference call by dialing (866) 211-3204 (U.S. and Canada) or (647) 689-6600 (international) using the conference ID: 8081886.

Other interested parties will be able to access the live audio webcast at this link: View Source The webcast will be recorded and will then be available on the IMV website for 30 days following the call.

On May 4, 2020 Coherus BioSciences, Inc. ("Coherus", Nasdaq: CHRS), reported that senior management will make a virtual presentation at BofA Securities 2020 Health Care Conference on Thursday, May 14, 2020 at 1:00 p.m. ET (Press release, Coherus Biosciences, MAY 4, 2020, View Source [SID1234556952]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The audio portion of the presentation will be available on the investors page of the Coherus BioSciences website at View Source

On May 4, 2020 Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL) therapeutic platform, reported dates for new data to be presented in abstract presentations at three upcoming medical meetings, as well as a management presentation at an investor conference in Spring 2020 (Press release, Phio Pharmaceuticals, MAY 4, 2020, View Source [SID1234556950]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

American Society of Gene & Cell Therapy (ASGCT) (Free ASGCT Whitepaper) 2020 Annual Meeting

Title:

Adoptive Cell Therapy don’t over engineer it; Alternatives to gene editing to improve cell-based therapeutics for the treatment of cancer

Date:

Tuesday, May 12, 2020

Presenter:

Dr. Simon P. Fricker

Abstract number:

1179

* This will be a virtual event in 2020 due to the COVID-19 pandemic

ASCO20 Virtual Scientific Program

Title:

Intratumoral use of self-delivering RNAi to reprogram the tumor microenvironment and boost the antitumor response

Date:

Friday, May 29, 2020

Presenter:

Dr. Gerrit Dispersyn

Abstract number:

e15206

* This will be a virtual event in 2020 due to the COVID-19 pandemic

American Association for Cancer Research (AACR) (Free AACR Whitepaper) Virtual Annual Meeting II

Title:

Intratumoral delivery of mPH-804 (TIGIT targeting INTASYL compound) inhibits tumor growth and confers an inflammatory tumor microenvironment

Date:

Monday, June 22, 2020

Session Title:

Immune Checkpoints 2

Presenter:

Dr. Simon P. Fricker

Abstract number:

5745

* This will be the second of two AACR (Free AACR Whitepaper) virtual annual meeting events being held in 2020 due to the COVID-19 pandemic

Sachs Associates 6th Annual Digital Immuno-oncology Innovation Forum

Date:

Wednesday, May 27, 2020

Time:

1:00 p.m. CST

Presenter:

Dr. Gerrit Dispersyn

Location:

* This will be a virtual event in 2020 due to the COVID-19 pandemic

The poster presentations and the corporate presentation will be made available under the "Investors – Events and Presentations" section of the Company’s website approximately one hour after each event.